Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05989997Phase 1Completed

Phase I Clinical Trial of 68Ga-NOTA-SNA002

Role: lead

NCT06646783Early Phase 1Not Yet Recruiting

Phase IIT Trial of SNA014

Role: lead

NCT05490264Early Phase 1Unknown

[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

Role: lead

NCT05126927Early Phase 1Completed

A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

Role: lead

All 4 trials loaded